EUVIMEDEuropean Health Evidence
Uhr Sources10/10 Journal Tree
Easy Demo

European Health Evidence

The European alternative to PubMed

EUVIMED is the European alternative to PubMed: a central, multilingual research platform for medicine, nursing, life sciences and healthcare. It brings together international and European literature sources, study registries, open-access full texts, citations and retraction notices in one search. Unlike pure bibliographic databases, EUVIMED supports the entire research process – from discovery and appraisal with LIVIA and CLARA to traceable evidence synthesis. European in focus, transparent, interoperable and designed for science and healthcare.

EuropeanMultilingualInteroperableTraceable

EUVIMED BETA

EUVIMED is currently in beta

EUVIMED is under continuous development. Features, data coverage and presentation may change or be temporarily incomplete.

Results are beta

Search results, classifications, summaries and AI-assisted assessments may be incomplete, delayed or incorrect.

Check original sources

Do not use EUVIMED results without verification for diagnosis, treatment or other clinical decisions. Always consult the original source and applicable guidelines.

Errors and feedback help us improve EUVIMED: info@euvimed.com

Lokaler Crossref-Datenbestand · journal-article

Herbal Formula AC591 Protects Against Cisplatin‐Induced Hearing Loss by Inhibiting p53‐Mediated Ferroptosis

Yunhao Wu, Yu Tao, Lin Wei, Qiuping Liu, Jiaxin Liu, Wen Jiang, Weiwei Shi, Peng Cao, Xiaolong Fu, Cheng Cheng

Smart Medicine · 2026

Vollständiger Abstract

Worum geht es in dieser Arbeit?

ABSTRACT Cisplatin is a widely utilized chemotherapeutic agent for the treatment of malignant cancers. However, its clinical application is significantly restricted due to its severe ototoxicity. Therefore, identifying protective medications to prevent cisplatin‐induced hearing loss (CIHL) is of paramount importance. Here, we show that AC591, derived from the classical herbal formula “Huangqi Guizhi Wuwu decoction,” exhibits notable protective effects on cisplatin‐induced ototoxicity. Our findings indicate that pretreatment with AC591 mitigates cisplatin‐induced auditory dysfunction, with its mechanism of action linked to the inhibition of p53‐mediated ferroptosis. By identifying the active components of AC591 in serum and cochlear tissues following oral administration, we recognized 18β‐glycyrrhetinic acid as an effective constituent for hearing protection. Furthermore, we confirmed that 18β‐glycyrrhetinic acid exerted otoprotective effects by binding to p53 and regulating proteins associated with ferroptosis. Collectively, our findings suggest that AC591 and 18β‐glycyrrhetinic acid may serve as promising agents for preventing CIHL.

Bibliografischer Nachweis

Publikationsdaten

Autor:innen
Yunhao Wu, Yu Tao, Lin Wei, Qiuping Liu, Jiaxin Liu, Wen Jiang, Weiwei Shi, Peng Cao, Xiaolong Fu, Cheng Cheng
Quelle
Smart Medicine
Publikation
2026-01-01
Band / Ausgabe
Nicht angegeben
Seiten
Nicht angegeben
ISSN / ISBN
2751-1871, 2751-1871
Zitationen
0 laut Crossref
Referenzen
0 hinterlegt

Zitieren

Zitierfähiger Nachweis

Yunhao Wu, Yu Tao, Lin Wei, Qiuping Liu, Jiaxin Liu, Wen Jiang, Weiwei Shi, Peng Cao, Xiaolong Fu, Cheng Cheng (2026). Herbal Formula AC591 Protects Against Cisplatin‐Induced Hearing Loss by Inhibiting p53‐Mediated Ferroptosis. Smart Medicine. https://doi.org/10.1002/smmd.70054
RIS BibTeX CSL-JSON

Kontext

Themen, Förderung und Nutzung

Lizenzhinweise: Lizenz 1 · Lizenz 2